Hengehold Capital Management’s ResMed RMD Stock Holding History

Hengehold Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-878	Closed	-$211K	–	228
2025 Q4	$211K	Hold	878	–	–	0.02%	213
2025 Q3	$240K	Buy	878 +6	+0.7%	+$1.64K	0.02%	200
2025 Q2	$225K	Buy	+872	New	+$208K	0.02%	197
2024 Q4	–	Sell	-872	Closed	-$213K	–	207
2024 Q3	$213K	Buy	+872	New	+$195K	0.02%	195

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hengehold Capital Management's RMD Position: Q1 2026 in Review

Hengehold Capital Management sold out of ResMed (RMD) in Q1 2026, closing a stake of 878 shares — an estimated $211K sold.

Hengehold Capital Management first reported a position in RMD in Q3 2024 and held it in 4 quarters. The position peaked at $240K in Q3 2025. 940 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Hengehold Capital Management reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
Hengehold Capital Management sold 878 ResMed shares in Q1 2026, an estimated $211K.
Hengehold Capital Management first reported a position in ResMed in Q3 2024 and held it in 4 quarters.
Hengehold Capital Management's ResMed position peaked at $240K in Q3 2025.
940 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Hengehold Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.